CClinicalTrials.gg
RecruitingNCT06600295ONDESUpdated Feb 19, 2026

Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action

An observational study in Newly Diagnosed Cancer of the Oropharynx, Oral Cavity, Colon or Liver, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
306
Ages
18 Years and older
Sex
All
01

Study summary

Cancers of the upper aerodigestive tract account for around 4% of all malignant tumours worldwide. Colon and liver cancer are the most common digestive cancers. The epidemiology of liver cancer is changing, and the number of deaths from liver cancer has increased by 25% worldwide (Huang 2022). In France, around 19,000 cancers of the upper aerodigestive tract and 88,000 new cases of digestive cancer are diagnosed each year (colon cancer remains the most common) (Globocan 2020). Patients with these two types of cancer are at particularly high risk of undernutrition (Pressoir 2010; Gyan 2018).

In cancer patients, changes in diet may result from constraints linked to the cancer or possible after-effects, but also from personal choices (for example, adopting a healthier diet). Cancer and its treatment lead to changes such as increased nutritional requirements and hypercatabolism, or sensory changes (taste and smell), reducing pleasure and food intake. These problems will impair quality of life and intensify undernutrition, a major problem in the management of the disease since it increases the risk of complications, therapeutic failure and mortality. It is estimated that 10-20% of deaths in cancer patients are attributable to the consequences of undernutrition rather than to the disease itself (Pressoir 2010). In the VICAN study, 41% of patients changed their diet after diagnosis: 29% because of changes in taste and 82% to have a healthier diet (INCa 2014). These changes were associated with the treatment received, the presence of sequelae and anxiety.

Taste and smell disorders are common in different types of cancer (any solid or haematological type) and treatments (chemotherapy, radiotherapy and surgery) (De Conno 1989; Heckel 2015; Spotten 2017; van Oort 2018). The mechanisms involved in sensory changes are not fully understood, especially in cancer, and with different types and treatments (Murtaza 2017). Several hypotheses have been proposed: altered expression of enzymes of the oral sphere, altered expression of sensory receptors (Neiers 2021), saliva composition and function (Zhu 2021), and impact of the oral microbiota (Schwartz 2021a, Licandro 2023).

The early identification of undesirable effects linked to nutrition, and the early or anticipated diagnosis of undernutrition are important issues in the management of cancer patients. The pleasure (or displeasure) produced by food guides desire and eating behaviour. The mechanisms involved are linked to hedonic sensations: conditioned satiety, specific sensory satiety, negative alliesthesia and the reward system (hedonic system). The latter is influenced by the environment and can be consciously controlled, with several dimensions: liking (the patient likes or dislikes a given food) and wanting (evaluates the desire to consume a given food at a given moment). All these parameters, together with sensory and dietary learning throughout life (habits, beliefs and constraints), influence food preferences and therefore eating behaviour. Individual sensitivities and the personal history of the disease (treatment and care pathway, sequelae, presence of co-morbidities, etc.) must therefore be taken into account when setting up preventive actions for cancer patients. It seems important to explore these factors, the experience of patients and the consequences for eating behaviour in daily life, in order to improve support and communication with healthcare professionals, as well as prevention and early detection of undernutrition. It would be interesting to conduct more in-depth studies on nutritional status, quality of life and changes in taste and smell, which in most studies have been considered separately.

02

Conditions studied

  • Newly Diagnosed Cancer of the Oropharynx, Oral Cavity, Colon or Liver
03

In context

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients will be identified :

  • at the department\'s multidisciplinary consultation meetings
  • during consultations with their referring doctor (ENT or gastroenterologist)

Inclusion criteria

Patient :

  • With newly diagnosed cancer of the oropharynx, oral cavity, colon or liver (at any stage).
  • For whom first-line treatment has been decided including radiotherapy, chemotherapy, immunotherapy and/or surgery.
  • Able to follow all study procedures in accordance with the protocol.
  • Have given their oral, free and informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Person not affiliated with national health insurance system
  • Person subject to a legal protection measure (curatorship, guardianship)
  • Pregnant women, women in labour or breastfeeding mothers
  • Adults who is unable to give consent
  • Minors
  • Person unable to read, speak, write and understand French
  • Patients with neuro-cognitive disorders (post-stroke, dyslexia, dyspraxia) or neuro-psychiatric disorders (dementia, autism) that make it impossible to assess taste sensoriality.
  • Patients with olfactory or gustatory disorders documented prior to the disease
  • Patient with another cancer currently being treated
  • Patients with a systemic disease or physical trauma affecting taste perception
  • Patients with kidney failure
  • Patients with sinonasal polyposis
  • Patients undergoing immunosuppressive treatment
  • Patients with an estimated life expectancy of less than 3 months
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
306 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with cancer of the oral cavity/oropharynx

    115 patients with cancer of the oral cavity/oropharynx

    Other: tests/questionnaires · Biological: biological samples · Other: evaluation

  • colon cancer patients

    123 colon cancer patients

    Other: tests/questionnaires · Biological: biological samples · Other: evaluation

  • patients with liver cancer

    68 patients with liver cancer

    Other: tests/questionnaires · Biological: biological samples · Other: evaluation

Interventions

  • Othertests/questionnaires

    EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS

  • Biologicalbiological samples

    blood, saliva, tongue mucus

  • Otherevaluation

    strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s

06

What researchers measure

Primary outcomes

  1. The presence or absence of undernutrition

    Time frame: Through study completion, an average of 12 months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06600295
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 6, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 19, 2026

Study contacts

Vanessa COTTET
Contact
Vanessa.cottet@u-bourgogne.fr
0380393487 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion